Zebrafish Avatar testing preclinical study predicts chemotherapy response in breast cancer

Chemotherapy remains the mainstay in most high-risk breast cancer (BC) settings, with several equivalent options of treatment. However, the efficacy of each treatment varies between patients and there is currently no test to determine which option will be the most effective for each individual patient. Here, we developed a fast in-vivo test for BC therapy screening: the zebrafish patient-derived-xenograft model (zAvatars), where in-vivo results can be obtained in just 10 days. To determine the predictive value of the BC zAvatars we performed a preclinical study, where zAvatars were treated with the same therapy as the donor-patient and their response to therapy was compared. Our data show a 100% concordance (18 out of 18) between the zAvatar-test and the corresponding patient's clinical response to treatment. Altogether, our results suggest that the zAvatar model constitutes a promising in-vivo assay to optimize cancer treatments in a truly personalized manner.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2025-04-01
DOI
https://doi.org/10.1038/s41698-025-00882-0
Citations
8
Primary Topic
Cell Image Analysis Techniques
Type
article
Field-Weighted Citation Impact
13.07

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Zebrafish Avatar testing preclinical study predicts chemotherapy response in breast cancer

Berta Sousa, Cátia Rebelo de Almeida, Fátima Cardoso, María José Brito et al.
8 citations
npj Precision Oncology
Cell Image Analysis Techniques
13.07
article

Zebrafish Avatar testing preclinical study predicts chemotherapy response in breast cancer

Berta Sousa, Cátia Rebelo de Almeida, Fátima Cardoso, María José Brito, Maria João Cardoso, Pedro Gouveia, Helena Gouveia, Rita Fior, Joana Ribeiro, Celeste Alves, Mireia Castillo-Martín, Miguel Godinho Ferreira, Rita Canas‐Marques, Raquel V. Mendes, Eva Batista
article en
8 citations

Abstract

Chemotherapy remains the mainstay in most high-risk breast cancer (BC) settings, with several equivalent options of treatment. However, the efficacy of each treatment varies between patients and there is currently no test to determine which option will be the most effective for each individual patient. Here, we developed a fast in-vivo test for BC therapy screening: the zebrafish patient-derived-xenograft model (zAvatars), where in-vivo results can be obtained in just 10 days. To determine the predictive value of the BC zAvatars we performed a preclinical study, where zAvatars were treated with the same therapy as the donor-patient and their response to therapy was compared. Our data show a 100% concordance (18 out of 18) between the zAvatar-test and the corresponding patient's clinical response to treatment. Altogether, our results suggest that the zAvatar model constitutes a promising in-vivo assay to optimize cancer treatments in a truly personalized manner.

npj Precision OncologyVol. 9(1)
Champalimaud Foundation (PT), Centre National de la Recherche Scientifique (FR), University of Lisbon (PT), Inserm (FR), Université Côte d'Azur (FR), Institut Gustave Roussy (FR), Institut de Recherche sur le Cancer et le Vieillissement de Nice (FR)
Howard Hughes Medical Institute, Fundação Champalimaud, Fundação para a Ciência e a Tecnologia
Openalex Percentile: Top 1%
Cell Image Analysis Techniques
13.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.